X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
human necessities (6) 6
hygiene (6) 6
medical or veterinary science (6) 6
preparations for medical, dental, or toilet purposes (6) 6
specific therapeutic activity of chemical compounds ormedicinal preparations (6) 6
humans (5) 5
double-blind method (4) 4
female (4) 4
index medicus (4) 4
middle aged (4) 4
abridged index medicus (3) 3
aged (3) 3
anticoagulants (3) 3
apixaban (3) 3
drug therapy (3) 3
follow-up studies (3) 3
life sciences (3) 3
male (3) 3
medicine, general & internal (3) 3
pyrazoles - adverse effects (3) 3
pyridones - adverse effects (3) 3
treatment outcome (3) 3
venous thromboembolism (3) 3
venous thromboembolism - drug therapy (3) 3
adult (2) 2
anticoagulants - adverse effects (2) 2
anticoagulants - therapeutic use (2) 2
bleeding (2) 2
clinical trials (2) 2
dosage and administration (2) 2
enoxaparin - adverse effects (2) 2
enoxaparin - therapeutic use (2) 2
events (2) 2
factor xa (2) 2
factor xa inhibitors (2) 2
heart attacks (2) 2
hemorrhage (2) 2
hemorrhage - chemically induced (2) 2
human health and pathology (2) 2
kaplan-meier estimate (2) 2
patients (2) 2
pulmonary-embolism (2) 2
pyrazoles (2) 2
pyrazoles - administration & dosage (2) 2
pyrazoles - therapeutic use (2) 2
pyridones (2) 2
pyridones - administration & dosage (2) 2
pyridones - therapeutic use (2) 2
risk (2) 2
risk factors (2) 2
thromboembolism (2) 2
veins & arteries (2) 2
warfarin - adverse effects (2) 2
warfarin - therapeutic use (2) 2
acute disease (1) 1
administration, oral (1) 1
aged, 80 and over (1) 1
angina (1) 1
antibodies - blood (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antibodies, monoclonal, humanized - immunology (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
antibodies; antibodies, monoclonal, humanized; anticholesteremic agents; cardiovascular diseases; cholesterol, ldl; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections, subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (1) 1
anticarcinogenic agents - therapeutic use (1) 1
anticholesteremic agents - adverse effects (1) 1
anticholesteremic agents - immunology (1) 1
anticholesteremic agents - therapeutic use (1) 1
anticoagulants - administration & dosage (1) 1
arterial cardiovascular events (1) 1
binomial trials (1) 1
biomarkers, tumor - metabolism (1) 1
blood clots (1) 1
bone density - drug effects (1) 1
bone density conservation agents - therapeutic use (1) 1
bone surgery (1) 1
breast cancer (1) 1
breast neoplasms - epidemiology (1) 1
breast neoplasms - metabolism (1) 1
breast neoplasms - prevention & control (1) 1
carcinoma, ductal, breast - epidemiology (1) 1
carcinoma, ductal, breast - metabolism (1) 1
carcinoma, ductal, breast - prevention & control (1) 1
cardiovascular disease (1) 1
cardiovascular diseases (1) 1
cardiovascular diseases - prevention & control (1) 1
case-control studies (1) 1
cerebral infarction (1) 1
cholesterol (1) 1
cholesterol, ldl - blood (1) 1
communication (1) 1
control (1) 1
coumarins (1) 1
creatinine (1) 1
creatinine - metabolism (1) 1
dabigatran (1) 1
disease prevention (1) 1
dose-response relationship (1) 1
drugs (1) 1
embolisms (1) 1
enoxaparin (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Limnology and Oceanography Bulletin, ISSN 1539-607X, 02/2019, Volume 28, Issue 1, pp. 32 - 33
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 9, pp. 799 - 808
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2013, Volume 368, Issue 8, pp. 699 - 708
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 16, pp. 1527 - 1539
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 11/2010, Volume 102, Issue 22, pp. 1706 - 1715
Background Currently available selective estrogen receptor modulators reduce the risk of breast cancer, but they are not widely used. In the Postmenopausal... 
IBIS | EVENTS | ONCOLOGY | RALOXIFENE | TAMOXIFEN | FOLLOW-UP | RISK | OUTCOMES | NSABP | INTERVENTION | PREVENTION TRIAL | Estradiol - blood | Receptors, Estrogen - blood | United States - epidemiology | Carcinoma, Ductal, Breast - epidemiology | Humans | Middle Aged | Osteoporosis, Postmenopausal - complications | Tetrahydronaphthalenes - therapeutic use | Case-Control Studies | Breast Neoplasms - metabolism | Incidence | Pyrrolidines - therapeutic use | Fractures, Bone - etiology | Selective Estrogen Receptor Modulators - therapeutic use | Aged, 80 and over | Biomarkers, Tumor - metabolism | Female | Carcinoma, Ductal, Breast - prevention & control | Odds Ratio | Carcinoma, Ductal, Breast - metabolism | Osteoporosis, Postmenopausal - prevention & control | Anticarcinogenic Agents - therapeutic use | Breast Neoplasms - epidemiology | Double-Blind Method | Risk Assessment | Bone Density Conservation Agents - therapeutic use | Sex Hormone-Binding Globulin - metabolism | Treatment Outcome | Mammography | Breast Neoplasms - prevention & control | Bone Density - drug effects | Fractures, Bone - complications | Primary Prevention - methods | Aged | Fractures, Bone - prevention & control | Osteoporosis | Control | Usage | Patient outcomes | Estrogen | Breast cancer | Postmenopausal women | Drug therapy | Health aspects | Womens health | Menopause | Risk factors | Index Medicus
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 11/2016, Volume 115, Issue 6, pp. 1159 - 1164
Summary Apixaban, a direct acting oral anticoagulant (DOAC), was found to be non-inferior to and safer as enoxaparin followed by warfarin for treatment of... 
Stroke, Systemic or Venous Thromboembolism
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 12/2016, Volume 116, Issue 6, pp. 1159 - 1164
Apixaban, a direct acting oral anticoagulant (DOAC), was found to be non-inferior to and safer as enoxaparin followed by warfarin for treatment of venous... 
Coumarins | Anticoagulants | Haemorrhage | Venous thromboembolism | Apixaban | DABIGATRAN | coumarins | venous thromboembolism | VITAMIN-K ANTAGONISTS | PERIPHERAL VASCULAR DISEASE | haemorrhage | HEMATOLOGY | apixaban
Journal Article
Survey of Anesthesiology, ISSN 0039-6206, 10/2013, Volume 57, Issue 5, pp. 263 - 264
Journal Article